Business
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
HAYWARD, Calif., February 23, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a pos
About this update from Arcus Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Median progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in an updated analysis of the ARC-20 study","length":207,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":207,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"In a pooled analysis of all four monotherapy cohorts (n=121), casdatifan data were better on every efficacy measure evaluated relative to published data from studies with the only marketed HIF-2a inhibitor","length":205,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":205,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"New biomarker data demonstrated correlation between magnitude and durability of serum erythropoietin (sEPO) suppression by casdatifan and clinical benefit, including cORR and PFS","length":178,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":178,"olType":false},{"type":"text","content":"HAYWARD, Calif., February 23, 2026--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a poster session on February 28, 2026, at the American Society of Clinical Oncology Genitourinary Cancer Symposium.","length":627,"tagName":"p"},{"type":"text","content":""Patients in the 100mg tablet cohort reached 15.1 months of PFS, and 45% had a confirmed response when treated with the same dose and formulation being used in the ongoing Phase 3 study," said Richard Markus, M.D., Ph.D., chief medical officer at Arcus Biosciences. "With longer follow-up, ORR continued to improve for both the 100mg QD cohort and pooled analysis, increasing meaningfully since the last analysis. Whether evaluating the pooled data or 100mg Phase 3 formulation data, PFS was two or nearly three times longer relative to published data from studies with the only...